AL
Insider
ARCH Venture Partners X, LLC
10% ownerARCH Venture Partners X, LLC (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in Neumora Therapeutics, Inc. (NMRA). Across 1 priced purchase filing, the average 21-session return was -19.5% from execution and -11.9% from disclosure (delay-adjusted; derived). The largest single filing was $5.0M of NMRA (1,915,700 sh × $2.61, as filed), executed Oct 27 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-19.5%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-11.9%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$5.0M
shares × price, as filed
Last traded
Oct 27 2025
Filed Oct 29 2025
Median ADV $3.2M across their filed names
Open performance→Volume by month
Buys $15.0M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
NMRARecent filings
NMRAPURCHASE
Neumora Therapeutics, Inc.
View filing →
$5.0M1,915,700 sh × $2.61
Exec Oct 27 2025
Filed Oct 29 2025 · 7:19 PM ET PRMEPURCHASE Prime Medicine, Inc. View filing → $10.0M
3,030,300 sh × $3.30
Exec Aug 1 2025
Filed Aug 1 2025 · 7:18 PM ET